Assoz.-Prof. PD Dr. Gerald Prager
ESMO 2019: Cholangiokarzinome sind nicht gleich Cholangiokarzinome
Assoz.-Prof. PD Dr. Gerald Prager, Universitätsklinik für Innere Medizin I, MedUni Wien, berichtet in seinen ESMO-Highlights zu nicht-kolorektalen GI-Tumoren von zwei vielversprechenden und einer negativen Studie.
Abstracts, die im Video diskutiert werden:
- Yau T et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). #BA38_PR
- Abou-Alfa GK et al. ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. # LBA10_PR
- Byoung CC et al. Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study. # LBA11
ESMO Congress 2019